Carcinologic Speech Severity Index

A Speech Disorders Severity Index to Measure the Impact of Oral and Pharyngeal Cavity on Speech Production

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02875795

Acronym

C2SI

Enrollment

124

Registered

2016-08-23

Start date

2015-01-01

Completion date

2017-12-31

Last updated

2020-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

linguistic, quality of life

Brief summary

The hypothesis of the present study is that an automatic assessment technic can measure the impact of the speech disorders on the communication abilities giving a severity index of speech in patients treated for head and neck and particularly for oral and pharyngeal cancer.

Interventions

PROCEDUREautomatic speech processing tool

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Oral and Pharyngeal cancer T2 to T4 for having a wide dynamic of deficit * Treatment by surgery and/or radiotherapy and/or chemotherapy * Delay after the end of the treatment of minimum 6 months.

Exclusion criteria

* Patients with a previous speech disorders (ie stuttering… ) * Patients not able to perform the whole task

Design outcomes

Primary

Measure	Time frame	Description
carcinologic speech severity index	day 0	The main objective is to demonstrate that the carcinologic speech severity index (C2SI), obtained by an automatic speech processing tool, produces equivalent or superior outcomes than a score of speech intelligibility obtained by human listeners, in terms of quality of life foreseeing the speech handicap, after the treatment of oral and/or pharyngeal cancer.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026